[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350385-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350385-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","differential-dna-damage-response-to-wrn-inhibition-identifies-a-targetable-vulnerability-in-arid1a-mutated-cancers","Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers","","ARID1A, a key SWI/SNF chromatin remodeling subunit, is frequently mutated in cancers, yet targeted options remain limited. This study identifies WRN as a critical vulnerability in ARID1A-mutated cancers. Genetic or pharmacologic WRN inhibition disrupts Chk1-mediated DNA damage signaling, triggers compensatory Chk2 activation, and drives G1 arrest with apoptosis, while ARID1A-proficient cells undergo Chk1-dependent G2-M arrest. Combining WRN inhibition with p21 suppression enhances cytotoxicity via mitotic catastrophe and demonstrates antitumor efficacy in xenograft models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/differential-dna-damage-response-to-wrn-inhibition-identifies-a-targetable-vulnerability-in-arid1a-mutated-cancers/350385/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/differential-dna-damage-response-to-wrn-inhibition-identifies-a-targetable-vulnerability-in-arid1a-mutated-cancers/350385.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic vulnerability is identified in ARID1A-mutated cancers?","Question",{"text":63,"@type":64},"Werner syndrome ATP-dependent helicase (WRN) is identified as a critical vulnerability in ARID1A-mutated cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does WRN inhibition affect DNA damage signaling differently by ARID1A status?",{"text":68,"@type":64},"In ARID1A-mutated cells, WRN inhibition leads to defective Chk1-mediated signaling, compensatory Chk2 activation, and G1 arrest with apoptosis, whereas ARID1A-proficient cells show Chk1-dependent G2-M arrest.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does combining WRN inhibition with p21 inhibition increase cell death?",{"text":72,"@type":64},"Additional p21 inhibition forces G1-arrested ARID1A-mutated cells to bypass arrest, resulting in mitotic catastrophe and enhanced cytotoxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350385,1790519620,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","CANCER  \nDifferential DNA damage response to WRN inhibition identifies a targetable vulnerability in  \nARID1A-mutated cancers  \nJiwon Kim1, Jaeik Oh2, Dongjun Jang1, Seungjae Shin1, Soo-Jin Lee1, Sang Eun Lee1, Yoojin Yang1, Dohee Kim1, Ae Jin Choi3, Hae Rim Jung3, Yumi Oh3, Sung-Yup Cho1,2,3,4*  \nARID1A (AT-rich interaction domain 1A), a key subunit of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex, is frequently mutated in cancers. However, effective clinical treatments for patients with this mutation are limited, highlighting a need for therapeutic strategies. Here, we identify Werner syndrome adenosine 5′-triphosphate–dependent helicase (WRN) as a critical vulnerability in ARID1A-mutated cancers. Upon genetic and pharmacological inhibition ofWRN, ARID1A-mutated cells had defective checkpoint kinase 1 (Chk1) -mediated DNA damage signaling, resulting in compensatory checkpoint kinase 2 (Chk2) activation, leading to G1 phase arrest and apoptosis, whereas ARID1A-proficient cells underwent Chk1-dependent G2-M arrest. Additional p21 inhibition in the context of WRN suppression promoted cell cycle reentry of G1-arrested ARID1A-mutated cells, resulting in enhanced cytotoxicity through mitotic catastrophe. The antitumor efficacy of WRN inhibition alone and in combination with p21 inhibition was validated using cell line–based xenograft and patient-derived xenograft mouse models. Our findings define WRN as a selective therapeutic target in ARID1A-mutated cancersand suggest a combinatorial strategy ofWRN and p21 inhibition as a therapeutic approach.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution noncommercial license 4.0 (cc BY-nc) .  \nINTRODUCTION  \nChromatin remodeling is a molecular process of modifying chromatin structure to regulate gene expression, and its dysregulation is associated with carcinogenesis (1). ARID1A (AT-rich interaction domain 1A), a core subunit of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex, is frequently mutated in many cancer types; its mutation accounts for ~6% of all cancer cases (2). ARID1A mutations are particularly prevalent in colorectal cancer (3), endometrial cancer (4), ovarian clear cell cancer (5), and gastric cancer (6). The high incidence of loss-of-function mutations in the ARID1A gene poses a major challenge for the development of targeted therapies in ARID1A-mutated cancers. To address this, several synthetic lethal targets have been suggested for ARID1A-mutated cancers, including ARID1B (7), enhancer of zeste homolog 2 (EZH2) (8), poly(adenosine 5′-diphosphate–ribose) polymerase (PARP) (9), ataxia telangiectasia and Rad3-related (ATR) (10), histone deacetylase 6 (HDAC6) (11), and aurora kinase A (AURKA)-CDC25C (12) . However, the clinical application of synthetic lethality–based therapeutics in ARID1A-mutant cancers remains limited, highlighting the limited availability of effective therapeutic options.  \nRecently, Werner syndrome adenosine 5′-triphosphate–dependent helicase (WRN) has been identified as a synthetic lethal target in microsatellite instability (MSI) cancers (13). WRN is a RecQ-like DNA helicase that plays a major role in the restart of homologous recombination–mediated replication forks and in preventing fork collapse (14). WRN depletion selectively induces cell death in MSI cancer cells, with loss ofthe helicase domain rather than the exonuclease domain ( 13). Moreover, WRN silencing leads to double-strand break (DSB)  \n1department of Biomedical Sciences, Seoul national University college of Medicine, Seoul 03080, Republic of Korea. 2department of translational Medicine, Seoul national University college of Medicine, Seoul 03080, Republic of Korea. 3Medical Research center, Genomic Medicine institute, Seoul national University college of Medicine, S","cbCaipybvhaqHYrg","https://ap.wps.com/l/cbCaipybvhaqHYrg","pdf",5050279,16,"English","# Introduction\n## WRN as a synthetic lethal target in MSI cancers\n## ARID1A mutations and therapeutic challenges\n# Results\n## Identification of WRN as a therapeutic vulnerability in ARID1A-mutated MSI cancers","[{\"question\":\"What therapeutic vulnerability is identified in ARID1A-mutated cancers?\",\"answer\":\"Werner syndrome ATP-dependent helicase (WRN) is identified as a critical vulnerability in ARID1A-mutated cancers.\"},{\"question\":\"How does WRN inhibition affect DNA damage signaling differently by ARID1A status?\",\"answer\":\"In ARID1A-mutated cells, WRN inhibition leads to defective Chk1-mediated signaling, compensatory Chk2 activation, and G1 arrest with apoptosis, whereas ARID1A-proficient cells show Chk1-dependent G2-M arrest.\"},{\"question\":\"Why does combining WRN inhibition with p21 inhibition increase cell death?\",\"answer\":\"Additional p21 inhibition forces G1-arrested ARID1A-mutated cells to bypass arrest, resulting in mitotic catastrophe and enhanced cytotoxicity.\"}]","Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers | PDF",1790088815,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7893b44cb48c5f5362f692868344fa87.webp",983,1250,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb36a0fb8952cb67f965875b51fe1379.webp",982,1249,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/728fb4320f826efd94b8bd32b33eac13.webp",981,1248,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f394749a2cd95a014d1863cf9ba640e5.webp",980,1247]